Previous 10 | Next 10 |
Bridgebio Pharma (NASDAQ: BBIO ) initiated with Buy rating and $42 (53% upside) price target at Goldman Sachs. Initiated with Buy rating and $38 price target at Jefferies. Initiated with Outperform rating and $49 price target at BMO. Initiated with Outperform rating and $34 price target at S...
We wrote an article comparing BioLife ( BLFS ) with CryoPort ( CYRX ) as we struggled to explain the tremendous valuation gap between the companies that operate in the same market. Data by YCharts Basically, we did see two possible explanations: CryoPort is more established in the ...
Shares of BioLife Solutions ( BLFS ) have risen by over 150% since my November 2017 article suggested readers establish a pilot position and accumulate dips in light of impressive Q3 results. Long time readers know I have a special place reserved for "picks and shovels"¨ ideas, compan...
BioLife Solutions ( BLFS +1.5% ) exercised its option to acquire the remaining 56% stake in privately held SAVSU Technologies in exchange for 1.1M BioLife shares. More news on: BioLife Solutions, Inc., Merger & acquisition news, Healthcare stocks news, Read more ...
BOTHELL, Wash. , July 8, 2019 /PRNewswire/ -- BioLife Solutions , Inc. (NASDAQ: BLFS), the leading developer, manufacturer and marketer of proprietary biopreservation media and automated cell thawing media devices for cell and gene therapies, today announced that it has exerci...
Here are two companies, BioLife Solutions ( BLFS ) and Cryoport ( CYRX ) which are both benefiting from the considerable tailwinds that come from the explosion in CAR-T and cell-based therapies that require preservation and transport of highly vulnerable tissues. The companies are basically ...
BOTHELL, Wash. , June 10, 2019 /PRNewswire/ -- BioLife Solutions , Inc. (NASDAQ: BLFS) ("BioLife" or the "Company"), the leading developer, manufacturer and marketer of proprietary biopreservation media and automated cell thawing devices for cell and gene therapies, today...
BOTHELL, Wash. , May 30, 2019 /PRNewswire/ -- BioLife Solutions , Inc. (NASDAQ: BLFS) ("BioLife" or the "Company"), the leading developer, manufacturer and marketer of proprietary biopreservation media and automated cell thawing devices for cell and gene therapies, t...
BOTHELL, Wash. , May 29, 2019 /PRNewswire/ -- BioLife Solutions, Inc. (NASDAQ: BLFS) ("BioLife" or the "Company"), the leading developer, manufacturer and marketer of proprietary biopreservation media and automated cell thawing devices for cell and gene therapies, tod...
BioLife Solutions ( BLFS ) is a stock to benefit from the early innings of regenerative medicine revolution with multiple avenues for growth ahead if it. Not only does it continue to gain new customers involved in clinical trials, but this also increases the pool of customers which eventuall...
News, Short Squeeze, Breakout and More Instantly...
BioLife Solutions Inc. Company Name:
BLFS Stock Symbol:
NASDAQ Market:
BioLife Solutions Inc. Website:
BioLife Solutions to Report Second Quarter 2024 Financial Results and Business Update on August 8, 2024 PR Newswire BOTHELL, Wash. , July 25, 2024 /PRNewswire/ -- BioLife Solutions , Inc. (NASDAQ: BLFS), a leading supplier of class-defining bioproduction...
BioLife Solutions Introduces the CellSeal CryoCase™ at International Society for Cell & Gene Therapies (ISCT) Conference in Vancouver BioLife Solutions Introduces the CellSeal CryoCase™ at International Society for Cell & Gene Therapies (ISCT) Conference in Vancouv...
BioLife Solutions Reports First Quarter 2024 Financial Results PR Newswire Cell Processing revenue increased 10% sequentially to $16.2 million GAAP gross margin of 38% and net loss of $10.2 million Non-GAAP adjusted gross margin expands ...